To Study Clinicopathological and Immunohistochemical Expression of Estrogen Receptor, Progesterone Receptor and Her-2/Neu in Prostate Carcinoma

  • Manpreet Kaur Department of Pathology, SGRD, Amritsar
  • Menka Khanna Department of Pathology, SGRD, Amritsar
  • Harjot Kaur Department of Pathology, SGRD, Amritsar
  • Rajeev Gupta Department of Medicine, SGRD, Amritsar
Keywords: Prostate carcinoma, ER, PR, HER-2/neu, Biomarkers


Background: Prostate carcinoma is leading cause of cancer related deaths amongst men. This study evaluated expression of ER, PR, HER-2/neu in Prostatic carcinoma and its correlation with Gleason score and other clinical parameters. Methods: 50 histopathologically proven PCa cases were subjected to IHC for ER, PR, HER-2/neu. Result:  Most common age group involved was 61-80years. Retention of urine was most frequent complaint.  Most prominent Gleason score was (3+4) and group grade was 2. ER expression in tumor epithelial cells was 24% and in stromal cells was 36%. PR expression in stromal cells was 32%. HER-2/neu Cytoplasmic positivity was seen in 6% cases. It was seen that with increase in Gleason grade, ER, PR, HER-2/neu positivity was decreased. Conclusion: ER, PR, HER-2/neu can be used as biomarkers in PCa management.


Jain S, Saxena S, Kumar A. Epidemiology of prostate cancer in India. Meta Gene. 2014;596-605.

Randolph TL, Amin MB, Ro JY, Ayala AG. Histologic variants of adenocarcinoma and other carcinomas of prostate cancer: pathologic criteria and clinical significance. Mod Pathol.1997;10:612-19.

Leach DA, Powell SM, Bevan CL. Women in cancer thematic review: new roles for nuclear receptors in prostate cancer. Endocrine-Related Cancer. 2016;23(11):T85-108.

Grimm, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J MolBiol.2016;428:3831–49.

Siampanopoulou A,Galaktidou G, Dimasis N, Gotzamani-Psarrakou A. Profiling serum HER-2/neu in prostate cancer. Hippokratia. 2013;17(2):108–12.

Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E et al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann Oncol. 2008; 19:269-75.

Naskar S, Kundu SK, Bhattacharya NK. A study to correlate histopathology, biochemical marker and immune–histochemical expression of sex steroid receptors in prostatic growth. Indian J PaediatrOncol.2014;35(1):40-3.

Naskar S, Kundu SK, Bhattacharya NK, Bhattacharya PK, Kundu AK. A study to correlate histopathology, biochemical marker and immune-histochemical expression of sex steroid receptors in prostatic growth. Indian J PaediatrOncol. 2014;35(1):40-3.

Chen N, Zhou Q.The evolving Gleason grading system. Chin J Cancer Res. 2016;28(1):58–64.

Darnel AD, Lafargue CJ, Vollmer RT, Corcos J,Bismar TA. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer BiolTher. 2009;8(2):125-30.

Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Makela S et al. Frequent loss of estrogen receptor-beta ex¬pression in prostate cancer. Cancer Res. 2001; 61: 5331-5.

Bonkhoff H. Progesterone receptor expression in human prostate cancer: correlation with tumor progression. Prostate. 2001;48(4):285–91.

Ady N, Morat L, Fizazi K, Soria JC, Mathieu MC, Prapotnich D et al. Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients. British Journal of Cancer. 2004;90(2):443-8.

Sahar Aly Daoud, Mohamed Faisal, Rehab Mohamed Sharaf. HER-2/neu immunostaining overexpression in Prostatic adenocarcinomas in relation to tumor pathological behavior. Middle East Journal of Scientific Research. 2016;24(2):459-64.

Original Article